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Abstract
Objective—To characterize in-hospital outcomes of premature infants diagnosed with severe 
bronchopulmonary dysplasia.
Study Design—Retrospective cohort study including premature infants with severe 
bronchopulmonary dysplasia discharged from 348 Pediatrix Medical Group neonatal intensive 
care units from 1997–2015.
Result—There were 10,752 infants with severe bronchopulmonary dysplasia, and 549/10,752 
(5%) died prior to discharge. Infants who died were more likely to be male, small for gestational 
age, have received more medical interventions, and more frequently diagnosed with surgical 
necrotizing enterocolitis, culture-proven sepsis, and pulmonary hypertension following 36 weeks 
postmenstrual age compared to survivors. Approximately 70% of infants with severe 
bronchopulmonary dysplasia were discharged by 44 weeks postmenstrual age, and 86% were 
discharged by 48 weeks postmenstrual age.
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Conclusion—A majority of infants diagnosed with severe bronchopulmonary dysplasia were 
discharged home by 44 weeks postmenstrual age. These results may inform discussions with 
families regarding the expected hospital course of infants diagnosed with severe 
bronchopulmonary dysplasia.
BACKGROUND
Bronchopulmonary dysplasia (BPD) is the most common and severe pulmonary 
complication of prematurity.1 The incidence of BPD may be increasing due to improvement 
in the survival of infants at earlier gestational ages (GA).2 The severity of BPD is correlated 
with long-term health outcomes. A consensus from the National Institutes of Health in 2001 
proposed the classification of BPD into mild, moderate, and severe categories based on the 
level of respiratory support at 36 weeks postmenstrual age (PMA).3 Compared to infants 
with mild or moderate BPD, infants with severe BPD are more likely to receive medications 
such as diuretics and bronchodilators, rehospitalized following discharge for pulmonary 
causes, and have more severe neurodevelopmental impairment at the 18–22 month follow up 
visit.4–7
Although infants with severe BPD have a longer initial hospitalization than their peers 
without BPD, antecedents, co-morbidities, and in-patient resource use in this population are 
not well-defined. In an effort to describe the clinical course of infants with severe BPD, we 
identified medical interventions and in-hospital clinical outcomes in infants born <−30 
weeks GA diagnosed with severe BPD. We hypothesized that infants with severe BPD who 
died during primary hospitalization were more likely to be born at earlier GAs and require 
more medical interventions than those infants who survived to discharge.
METHODS
Data Source and Study Population
We obtained data from the Pediatrix Medical Group Clinical Data Warehouse, which 
prospectively captures clinical information entered into an electronic health record by 
clinicians at 348 neonatal intensive care units.8 We extracted information on prenatal 
characteristics, demographics, exposure to medications, and interventions while in the 
hospital, as well as in-hospital clinical outcomes and level of respiratory support at time of 
death or discharge. We included all inborn infants <30 weeks of GA discharged between 
1997 and 2015 and diagnosed with severe BPD. We excluded infants discharged prior to 36 
weeks PMA and those with missing data on mortality.
Definitions
We defined severe BPD as those infants receiving positive pressure (defined as nasal 
continuous positive airway pressure (CPAP), high-flow nasal cannula (HFNC) (>1 L/min), 
nasal intermittent positive pressure ventilation (PPV), conventional ventilation or high-
frequency ventilation) at 36 weeks PMA. We did not include infants receiving supplemental 
oxygen ≥30% via low-flow nasal cannula (LFNC, ≤ 1 L/min) in our definition as we wanted 
to identify the most severe cases of BPD and the actual oxygen concentration delivered via 
LFNC varies depending on the size of the nares, the amount of mouth breathing, and the 
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infant’s tidal volume and inspiratory time.9,10 Furthermore, data from the Pediatrix Medical 
Group Clinical Data Warehouse includes a single measurement of oxygen requirement for a 
given day, which would not conform to the current NICHD definition of severe BPD. We 
defined small for gestational age as <10th percentile for age at birth as described by Olsen.11 
We identified exposures to medical interventions including the use of diuretics 
(acetazolamide, amiloride, bumetanide, chlorothiazide, diazoxide, ethacrynic acid, 
furosemide, hydrocholorothiazide, metolazone, and spironolactone), sildenafil, stimulants 
(aminophylline, doxapram, caffeine, and theophylline), steroids (dexamethasone, 
prednisolone, and prednisone), inhaled medications (budesonide, albuterol, and 
levalbuterol), and inhaled nitric oxide. We examined the incidence of in-hospital outcomes 
including sepsis, defined as bacteremia with an organism not typically considered a 
contaminant, intraventricular hemorrhage grade III or IV, surgical NEC, pulmonary 
hypertension as a diagnosis by the clinician, gastrostomy tube placement, and tracheostomy 
prior to and following diagnosis of severe BPD.
In order to show the evolving clinical course throughout hospitalization, we reviewed the 
level of respiratory support in 4-week intervals for those infants who remained hospitalized 
following the diagnosis of severe BPD. We also included the number of infants who had 
died, had been discharged, or remained in-hospital at each of the 4-week intervals following 
diagnosis of BPD.
Statistical Analysis
The unit of observation for this study was the infant. We used standard summary statistics, 
including medians (interquartile ranges) and counts (percentages), to describe categorical 
study variables. We compared distributions of study variables across categories using 
Wilcoxon rank sum, Chi square, and Fisher’s exact tests where appropriate. All analyses 
were performed using Stata SE 14.2 (StataCorp, College Station, TX) and assumed a 
significance limit of α = 0.05. The study was approved by the Duke University Health 
System Institutional Review Board without the need for written informed consent as the data 
were collected without identifiers.
RESULTS
We identified 10,752 infants diagnosed with severe BPD at 36 weeks PMA. The number of 
infants with severe BPD who died prior to discharge was 549/10,752 (5%). At the time of 
diagnosis, 2525/10,752 (23%) were receiving mechanical ventilation, and 8227/10,752 
(77%) were receiving HFNC, CPAP, or nasal intermittent positive-press ventilation. The 
median GA and birth weight of the cohort were 26 weeks (interquartile range; 25, 27) and 
755 g (628, 920), respectively. Median GA and birth weight were lower in the infants who 
died compared with those who survived to discharge, GA 25 weeks (24, 27) vs. 26 weeks 
(25, 27), p = 0.003, and birth weight 650 g (560, 810) vs. 760 g (630, 925), p <0.001. Infants 
who died were more likely male and small for gestational age (Table 1). Infants that died 
were more likely to be exposed to diuretics, inhaled medications, sildenafil, stimulants, 
steroids and inhaled nitric oxide prior to 36 weeks PMA (Table 2). No statistically 
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significant difference was found in the exposure to surfactant or supplemental oxygen 
between the two groups.
Several events were diagnosed more frequently prior to 36 weeks PMA in infants who died 
compared to those who survived, including intraventricular hemorrhage, surgical NEC, 
pulmonary hypertension, and culture-proven sepsis (Table 3). Diagnosis of surgical NEC, 
pulmonary hypertension, and culture-proven sepsis after 36 weeks PMA occurred more 
frequently in infants who died compared to those who survived. Infants who died were more 
likely to receive mechanical ventilation after diagnosis than the group who survived to 
discharge (97% vs. 39%, p <0.001) and received more days on the ventilator until death or 
discharge, median number of days 31, (11–64) vs 0, (0–4). Following diagnosis, 1019 
infants (10%) who survived received a g-tube compared to 77 infants (14%) who died (p = 
0.002), and 302 infants (3%) who survived received a tracheostomy compared to 64 infants 
(12%) who died (p <0.001). Fifty-seven percent of infants discharged from the hospital 
received supplemental oxygen, and 3% received mechanical ventilation at the time of 
discharge (Supplementary Table 1).
An increasing proportion of infants remaining hospitalized received mechanical ventilation 
(Figure 1). While 24% of infants received some form of mechanical ventilation at 36 weeks 
PMA, this number increased to 48% in those infants remaining hospitalized at 56 weeks 
PMA. Seventy percent of infants with severe BPD were discharged by 44 weeks PMA and 
86% were discharged by 48 weeks PMA (Table 4). The time period with the largest number 
of deaths occurred between 36 and 40 weeks PMA. Of the 2525 infants receiving 
mechanical ventilation at 36 weeks PMA, 1860 (74%) were discharged home prior to 52 
weeks PMA, 336 (13%) died, and 329 (13%) remained hospitalized at 52 weeks PMA. Of 
the 8117 infants receiving HFNC or CPAP at 36 weeks PMA, 7907 (96%) were discharged 
prior to 52 weeks PMA, 108 (1%) died, and 212 (3%) remained hospitalized at 52 weeks 
PMA.
DISCUSSION
We found that the majority of infants diagnosed with severe BPD at 36 weeks PMA survive 
until discharge and that most are discharged by 44 weeks PMA. An important caveat is that 
mortality in this study does include infants who died prior to the diagnosis of BPD at 36 
weeks PMA. While all of the infants included in our study received positive pressure at the 
time of diagnosis, the proportion of infants receiving some form of positive pressure 
decreased at 40 weeks PMA, and actually increased thereafter. For example, after 44 weeks 
PMA, an increasingly higher percentage of infants remaining hospitalized received 
mechanical ventilation, likely reflecting that the most critically ill infants had a longer 
duration of primary hospitalization. These results suggest that at the estimated date of 
delivery, about two-thirds of infants with severe BPD will remain hospitalized and a 
relatively small percentage of these hospitalized infants will receive mechanical ventilation. 
This information may help inform discussions with families regarding the expected hospital 
course of infants diagnosed with severe BPD.
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We found that about half of infants diagnosed with severe BPD were exposed to postnatal 
dexamethasone, prednisone, or prednisolone. Approximately 40% of infants in our cohort 
received these steroids prior to 36 weeks PMA and those who subsequently died were more 
likely to receive steroids (49% vs. 37%). The proposed benefits of steroids in the infant 
include enhancement of endogenous surfactant and anti-oxidant production, amelioration of 
the inflammatory process contributing to the development of BPD, and reduction of 
pulmonary edema and bronchospasm, all of which may reduce the incidence of BPD. The 
most recent American Academy of Pediatrics guidelines on the use of postnatal steroids in 
premature infants at risk for BPD advise clinicians to, while consulting the infant’s parents, 
balance the risks of using a short course of low-dose corticosteroids against the risks of 
evolving pulmonary disease and prolonged mechanical ventilation.12
We found that a lower percentage of infants who died (79%) were exposed to stimulant 
therapy prior to 36 weeks PMA compared to those infants who survived (93%). While this 
finding is surprising, we speculate that some of the infants who received prolonged 
mechanical ventilation may not have been started on stimulant therapy as extubation was not 
anticipated and central apnea cannot occur while on mechanical ventilation. Several studies 
have found that early administration of caffeine in premature infants is associated with an 
increase in survival without BPD.13–15 The early use of caffeine should be strongly 
considered in infants at high risk for BPD regardless of respiratory support.
Premature infants with a diagnosis of BPD were found to require a high number of primary 
care provider office visits and prescription medications in the first year of life.16 About 3% 
of infants in our study who were discharged home received mechanical ventilation, with 
approximately the same number receiving tracheostomy. More than half of infants with 
severe BPD discharged home received supplemental oxygen. Previous investigators found 
that premature infants with BPD who were discharged home with supplemental oxygen were 
more likely to receive respiratory medications, supplemental oxygen, and more frequent 
physician visits at 36 months of life compared with infants with BPD who were discharged 
home without supplemental oxygen.17 Approximately one in ten infants in our study who 
survived to discharge received a gastrostomy tube during primary hospitalization. Infants 
with BPD who receive gastrostomy tubes were found to have longer primary 
hospitalizations, are more likely to receive ventilatory support and supplemental oxygen at 
the time of discharge, and are more likely to be rehospitalized in the first two years of life 
compared to infants with BPD who do not receive gastrostomy tubes.18
There are several limitations to our study. As the purpose of our study was to determine in-
hospital outcomes in premature infants diagnosed with severe BPD, we did not include 
infants who died prior to 36 weeks PMA or infants who were transferred to other facilities 
outside the network. Our definition of severe BPD was based on the use of positive pressure 
at 36 weeks PMA. The inclusion of HFNC (considered >1 L/min via nasal cannula) in our 
definition of PPV does not directly measure distending pressure because the measured 
component is liter flow.19,20 HFNC is an increasingly common modality used in neonatal 
intensive care units worldwide due to its perceived benefits in ease of use compared to nasal 
CPAP.21,22 We included HFNC as PPV because we believe that the intent by the clinician 
was to provide PPV, even though the exact distending pressure is unmeasured. While infants 
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receiving LFNC (considered <1 L/min) with a fraction of inspired oxygen ≥0.3 at 36 weeks 
PMA would be considered to have severe BPD based on the 2001 National Institutes of 
Health consensus, we did not include these infants in our definition of BPD as the oxygen 
concentration which an infant receives via nasal cannula is not precise.23 This is due to the 
entrainment of room air through the mouth and nose, which may result in the delivery of a 
lower fraction of inspired oxygen than what is recorded. A further limitation is that the 
diagnosis of pulmonary hypertension was based on documentation by clinicians and no 
echocardiogram images or reports were reviewed for this study.
In summary, we describe the in-hospital outcomes of premature infants born <30 weeks GA 
who were subsequently diagnosed with severe BPD. The majority were discharged home by 
44 weeks PMA and a small percentage of these infants died. The infants receiving prolonged 
mechanical ventilation were more likely to remain hospitalized and of those infants who 
died, nearly all (>90%) died while receiving mechanical ventilation. While the incidence of 
severe BPD is relatively rare compared to the number of premature infants born each year 
worldwide, the substantial health care resources and familial stress associated with an 
increased morbidity and mortality, including prolonged hospitalization, demand further 
efforts to prevent and more effectively treat infants with severe BPD. Further studies using 
large sample sizes in collaboration with multiple clinical sites will be required to determine 
long-term pulmonary and neurodevelopmental outcomes in these infants and develop 
potential therapies to prevent and treat BPD.
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Figure 1. Respiratory support over time in hospitalized premature infants with severe BPD
Abbreviations: HFNC = high-flow nasal cannula; CPAP = continuous positive airway 
pressure; NIPPV = nasal-intermittent positive pressure ventilation; CV = conventional 
mechanical ventilation; HFV = high-frequency ventilation
Jackson et al. Page 8
J Perinatol. Author manuscript; available in PMC 2017 October 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Jackson et al. Page 9
Table 1
Cohort demographics
Survived
N= 10,203
Died
N= 549
P-value
Antenatal steroids 8540 (84%) 445 (81%) 0.10
Antenatal antibiotics 4682 (46%) 239 (44%) 0.28
Cesarean section 7688 (76%) 418 (77%) 0.80
Male 5799 (57%) 341 (62%) 0.01
Gestational age (weeks) < 0.001
 ≤ 25 4421 (43%) 279 (51%)
 26–28 4866 (48%) 211 (38%)
 29 916 (9%) 59 (11%)
Birth weight (g) <0.001
 <1000 8365 (82%) 487 (89%)
 1000–1499 1777 (17%) 59 (11%)
 1500–2499 58 (< 1%) 3 (< 1%)
SGA 2471 (24%) 225 (41%) <0.001
SGA = small for gestational age
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